New business focuses on developing data assets, software, and AI to fuel life science breakthroughs
Expands pharma access to large omics datasets to advance target discovery and drug development
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, understand biological pathways, discover novel disease mechanisms, and build the next wave of biological insights. This move reflects Illumina's commitment to delivering innovative solutions to advance science and health care, and fuels the company's long-term, sustainable growth.
BioInsight will be led by Rami Mehio as senior vice president and general manager. Mehio has led Illumina's Global Software & Informatics team for four years and now joins the company's executive leadership team.
"Working together with our customers, we are going beyond sequencing and breaking the barrier between omics data generation and transformative insights," said Jacob Thaysen, chief executive officer of Illumina. "BioInsight, under Rami's guidance, will strengthen Illumina's leadership at the intersection of sequencing, software, and AI, with a focus on supporting pharma in drug target discovery and development."
BioInsight key focus areas:
"We are at a pivotal moment in science and technology," Mehio said. "The dramatic reduction in sequencing costs has unlocked the ability to generate multiomic data at an unprecedented scale. At the same time, we are witnessing an extraordinary rise in AI capabilities. The confluence of these two forces is transforming how we derive biological insights, and Illumina is committed to partnering with our customers and collaborators to develop the largest, highest-quality datasets and the AI-driven tools that turn this data into meaningful discoveries."
The role of AI, informatics, and insights in life science innovation
Progress in the life sciences is accelerating as researchers gain the ability to collect and interpret vast amounts of multiomic data. Today, the field is generating more data than ever before, and advanced AI and software are vital to deriving actionable insights from complex multimodal datasets. Ultimately, these insights hold the power to accelerate drug target discovery, disease diagnosis, and therapeutic development. Illumina is organizing its new business to support essential functions that make this possible.
Multimodal data generation and aggregation - BioInsight will support data generation in three main ways: enabling large national research initiatives, working with corporate partners to develop valuable data assets, and facilitating large-scale federated data networks. This includes expanding beyond traditional genomics to include multiomic and advanced biological data types, such as perturb-seq.
AI and tool development - BioInsight is designed to harness all available multimodal data, creating the tools and resources needed to help customers and partners achieve meaningful results faster. With these tools, scientists can more quickly identify patterns, discover new drug targets, and improve disease diagnosis and treatment. In addition to developing its own tools and models, Illumina looks to partner with industry leaders to enable a broad ecosystem of tools to be developed leveraging its data assets.
With intent focus on the growth of scalable data and AI solutions, BioInsight and Illumina will drive customer access to rich omics data insights, faster and more efficiently, to accelerate transformative research and discovery.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Illumina Investor Relations
858-291-6421
[email protected]
Media:
Christine Douglass
[email protected]
SOURCE Illumina, Inc.
Share this article